Literature DB >> 31059734

Comparison of clinical and immunological features and mortality in common variable immunodeficiency and agammaglobulinemia patients.

Yasser Bagheri1, Ahmad Vosughi2, Gholamreza Azizi3, Reza Yazdani4, Fatemeh Kiaee5, Nasim Hafezi6, Shahriar Alimorad7, Majid Khoshmirsafa8, Farhad Seif9, Gholamreza Hassanpour10, Hassan Abolhassani11, Asghar Aghamohammadi12.   

Abstract

Common Variable Immunodeficiency (CVID) and agammaglobulinemia are two of the main types of symptomatic primary antibody deficiencies. The pathogenic origins of these two diseases are different; agammaglobulinemia is a group of inherited disorders that usually are caused by mutations in the gene encoding Bruton Tyrosine Kinase (BTK) protein while CVID is a heterogeneous disorder mainly without monogenic cause. However, both diseases share a characteristic of frequent bacterial infections, a decline in serum immunoglobulin levels, and abnormality in antibody responses. The demographics and immunologic parameters, clinical manifestation, and mortality statistics from 297 patients with CVID and agammaglobulinemia followed up over 2 decades in the Children's Medical Center of Iran. Age at onset of symptom in agammaglobulinemia was earlier than CVID but the course of disease in CVID patients was longer than agammaglobulinemia patients. Pulmonary infections were the most prevalent clinical manifestations in both groups of patients. Lymphadenopathy, hepatomegaly, and splenomegaly were significantly higher in CVID patients than agammaglobulinemia patients and there was a significant association between these complications and mortality in CVID patients. Among 297 patients, 128 patients (88 CVID and 40 agammaglobulinemia) deceased. The predominant causes of death in CVID patients were infections, chronic lung disease, and malignancy while in agammaglobulinemia patients were infections and respiratory failure. Infections, especially respiratory infections were the most common complication and cause of death in both CVID and agammaglobulinemia groups and recent treatment advances even Immunoglobulin replacement cannot completely control these complications. Thus prompt recognition and specific management of these complications are worthwhile.
Copyright © 2019 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Agammaglobulinemia; Clinical manifestation; Common variable immunodeficiency; Infections; Mortality

Mesh:

Substances:

Year:  2019        PMID: 31059734     DOI: 10.1016/j.imlet.2019.05.001

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

1.  Pulmonary Disease Burden in Primary Immune Deficiency Disorders: Data from USIDNET Registry.

Authors:  Meera Patrawala; Ying Cui; Limin Peng; Ramsay L Fuleihan; Elizabeth K Garabedian; Kiran Patel; Lokesh Guglani
Journal:  J Clin Immunol       Date:  2020-01-09       Impact factor: 8.317

2.  Primary antibody deficiencies in Turkey: molecular and clinical aspects.

Authors:  Sinem Firtina; Yuk Yin Ng; Ozden H Ng; Ayca Kiykim; Esra Yucel Ozek; Manolya Kara; Elif Aydiner; Serdar Nepesov; Yildiz Camcioglu; Esra H Sayar; Ezgi Yalcin Gungoren; Ismail Reisli; Selda H Torun; Sule Haskologlu; Tuba Cogurlu; Aysenur Kaya; Sukru Cekic; Safa Baris; Ugur Ozbek; Ahmet Ozen; Muge Sayitoglu
Journal:  Immunol Res       Date:  2021-10-07       Impact factor: 2.829

3.  [Common variable immune deficiency in adult patients: analysis of 13 cases and literature review].

Authors:  Shenglan Gong; Yin Pu; Lingli Xie; Xiaoya Yang; Hui Mao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-08-30

Review 4.  Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.

Authors:  Giorgio Costagliola; Rita Consolini
Journal:  Clin Exp Immunol       Date:  2021-06-20       Impact factor: 4.330

Review 5.  Heterogeneity of Liver Disease in Common Variable Immunodeficiency Disorders.

Authors:  Antonio Pecoraro; Ludovica Crescenzi; Gilda Varricchi; Giancarlo Marone; Giuseppe Spadaro
Journal:  Front Immunol       Date:  2020-02-28       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.